Excellent
Mostly Aligned
Patient Risk:
Low
Summary
The evaluated content is a suicidality/monitoring claim supported by the provided FDA label text in SECTION 5 (Clinical Worsening and Suicide Risk in Treating Psychiatric Disorders). No contradictions were identified within the supplied label excerpt.
Category Scores
Accurate Statements
Patients with major depressive disorder may experience worsening of depression and/or emergence of suicidal ideation and behavior (suicidality) and/or unusual changes in behavior during early phases of antidepressant treatment.
SECTION 5 — Clinical Worsening and Suicide Risk in Treating Psychiatric Disorders.
Pooled analyses of short-term placebo-controlled trials show antidepressants increase risk of suicidal thinking and behavior (suicidality) in children, adolescents, and young adults ages 18 to 24 with MDD and other psychiatric disorders.
SECTION 5 — Clinical Worsening and Suicide Risk in Treating Psychiatric Disorders.
All patients treated with antidepressants should be monitored appropriately and observed closely for clinical worsening, suicidality, and unusual behavior changes, especially during the initial few months and during dose changes.
SECTION 5 — Clinical Worsening and Suicide Risk in Treating Psychiatric Disorders.
Consider changing the therapeutic regimen, including possibly discontinuing, in patients with persistently worse depression or emergent suicidality or symptoms that might be precursors, especially if severe, abrupt, or not part of presenting symptoms.
SECTION 5 — Clinical Worsening and Suicide Risk in Treating Psychiatric Disorders.
Families and caregivers should be alerted to monitor for agitation, irritability, unusual changes in behavior, and emergence of suicidality and report such symptoms immediately.
SECTION 5 — Clinical Worsening and Suicide Risk in Treating Psychiatric Disorders.
Unsupported Statements
The label content is framed generally for 'antidepressants' in psychiatric disorders; however, it explicitly requires monitoring for clinical worsening/suicidality and describes increased risk in younger patients.
This is not a factual claim about the drug label text beyond what is already supported; it is an interpretive framing. The underlying monitoring and increased risk statements are supported, so this specific framing adds no additional label-supported detail.
Contradictions
Important Omissions
The evaluated claim did not specify the label’s instruction to prescribe WELLBUTRIN XL for the smallest quantity consistent with good patient management to reduce the risk of overdose.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The claim aligns with the label’s suicidality/clinical worsening monitoring guidance in SECTION 5; no contradictory or unsafe instructions were identified in the provided evaluation content.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Omission of the label’s specific additional instruction about limiting quantities prescribed to reduce overdose risk.
Suggested Improvement
Include the label’s guidance to write WELLBUTRIN XL prescriptions for the smallest quantity consistent with good patient management to reduce the risk of overdose, when summarizing monitoring/safety instructions.